News

CLINUVEL
Posted by CLINUVEL
July 26, 2023

SCENESSE® applied under five-year Veterans Affairs contract

CLINUVEL has been awarded a five-year contract by the U.S. Department of...

Read More
CLINUVEL
Posted by CLINUVEL
July 14, 2023

CLINUVEL secures IP for melanocortins to treat central nervous system disorders

CLINUVEL has secured a family of patents and patent applications relating to...

Read More
CLINUVEL
Posted by CLINUVEL
June 30, 2023

Notification regarding unquoted securities

CLINUVEL today released a notification regarding unquoted securities.

Read More
CLINUVEL
Posted by CLINUVEL
June 30, 2023

Two grounds of Appeal upheld by NICE Panel

In an announcement released today, CLINUVEL provided an updated on the outcome...

Read More
CLINUVEL
Posted by CLINUVEL
June 30, 2023

News Kommuniqué III

Melbourne, Australia, 26 June 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...

Read More
CLINUVEL
Posted by CLINUVEL
June 29, 2023

Notification of cessation of securities

CLINUVEL today released a notification regarding cessation of securities.

Read More
CLINUVEL
Posted by CLINUVEL
June 29, 2023

Twilight Event - Briefing

CLINUVEL presented during a Twilight Briefing, after the close of market yesterday....

Read More
CLINUVEL
Posted by CLINUVEL
June 28, 2023

Change of Director’s Interest Notice

CLINUVEL today released a notification regarding a change of Director’s interest.

Read More
CLINUVEL
Posted by CLINUVEL
June 26, 2023

News Communiqué III

CLINUVEL’s News Communiqué III reviews the Company’s trajectory, and underlying reasons to...

Read More
CLINUVEL
Posted by CLINUVEL
June 1, 2023

Strategic Update VI

CLINUVEL today announced its sixth Strategic Update.

Read More
CLINUVEL
Posted by CLINUVEL
May 31, 2023

CLINUVEL Bulletin Edition 01

The first in a new series providing updates on CLINUVEL's Brand Architecture,...

Read More
CLINUVEL
Posted by CLINUVEL
May 9, 2023

CLINUVEL escalates PRÉNUMBRA® to moderate/severe stroke patients

CLINUVEL announced the escalation of PRÉNUMBRA® Instant to moderate-to-severe and severe stroke...

Read More
CLINUVEL
Posted by CLINUVEL
May 1, 2023

Expansion of CLINUVEL’s global porphyria programs

CLINUVEL today released an update on the use its drug SCENESSE® (afamelanotide...

Read More
CLINUVEL
Posted by CLINUVEL
April 11, 2023

News Kommuniqué II

Melbourne, Australia, 12 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...

Read More
CLINUVEL
Posted by CLINUVEL
April 7, 2023

News Communiqué I - Ms Cristina Ramos

Introducing CLINUVEL’s next Intriguing Personality (CUVIP), Ms Cristina Ramos.

Read More